keyword
https://read.qxmd.com/read/38638377/treatment-options-for-hepatocellular-carcinoma-using-immunotherapy-present-and-future
#21
REVIEW
Hongbin Wei, Chunlu Dong, Xun Li
Hepatocellular carcinoma (HCC) is a common cancer, and the body's immune responses greatly affect its progression and the prognosis of patients. Immunological suppression and the maintenance of self-tolerance in the tumor microenvironment are essential responses, and these form part of the theoretical foundations of immunotherapy. In this review, we first discuss the tumor microenvironment of HCC, describe immunosuppression in HCC, and review the major biomarkers used to track HCC progression and response to treatment...
April 28, 2024: Journal of Clinical and Translational Hepatology
https://read.qxmd.com/read/38637848/tea-polyphenol-engineered-hybrid-cellular-nanovesicles-for-cancer-immunotherapy-and-androgen-deprivation-therapy
#22
JOURNAL ARTICLE
Yiming Guo, Jicheng Wu, Lefan Chen, Lujie Liu, Tianxiang Bi, Yuanwei Pan, Qian-Fang Meng, Chaoliang Wang, Lang Rao, Qi Li
Androgen deprivation therapy (ADT) is a crucial and effective strategy for prostate cancer, while systemic administration may cause profound side effects on normal tissues. More importantly, the ADT can easily lead to resistance by involving the activation of NF-κB signaling pathway and high infiltration of M2 macrophages in tumor microenvironment (TME). Herein, we developed a biomimetic nanotherapeutic platform by deriving cell membrane nanovesicles from cancer cells and probiotics to yield the hybrid cellular nanovesicles (hNVs), loading flutamide (Flu) into the resulting hNVs, and finally modifying the hNVs@Flu with Epigallocatechin-3-gallate (EGCG)...
April 18, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38636895/galectin-3-depletion-tames-pro-tumoural-microglia-and-restrains-cancer-cells-growth
#23
JOURNAL ARTICLE
Alberto Rivera-Ramos, Luis Cruz Hernández, Rocío Talaverón, María Teresa Sánchez Montero, Juan García-Revilla, Marta Mulero-Acevedo, Tomas Deierborg, José Luis Venero, Manuel Sarmiento Soto
Galectin-3 (Gal-3) is a multifunctional protein that plays a pivotal role in the initiation and progression of various central nervous system diseases, including cancer. Although the involvement of Gal-3 in tumour progression, resistance to treatment and immunosuppression has long been studied in different cancer types, mainly outside the central nervous system, its elevated expression in myeloid and glial cells underscores its profound impact on the brain's immune response. In this context, microglia and infiltrating macrophages, the predominant non-cancerous cells within the tumour microenvironment, play critical roles in establishing an immunosuppressive milieu in diverse brain tumours...
April 16, 2024: Cancer Letters
https://read.qxmd.com/read/38636892/nucb2-inhibition-antagonizes-osteosarcoma-progression-and-promotes-anti-tumor-immunity-through-inactivating-nucks1-cxcl8-axis
#24
JOURNAL ARTICLE
Renchen Ji, Yuan Wang, Deyue Pan, Jian Han, Yiping Wang, Shuo Zheng, Wenzhi Zhao, Xiaojie Li, Chuanchun Han, Lu Zhang
The oncogenic properties of Nucleobindin2 (NUCB2) have been observed in various cancer types. Nevertheless, the precise understanding of the biological functions and regulatory mechanisms of NUCB2 in osteosarcoma remains limited. This investigation reported that NUCB2 was significantly increased upon glucose deprivation-induced metabolic stress. Elevated NUCB2 suppressed glucose deprivation-induced cell death and reactive oxygen species (ROS) increase. Depletion of NUCB2 resulted in a reduction in osteosarcoma cell proliferation as well as metastatic potential in vitro and in vivo...
April 16, 2024: Cancer Letters
https://read.qxmd.com/read/38635899/cd106-in-tumor-specific-exhausted-cd8-t-cells-mediates-immunosuppression-by-inhibiting-tcr-signaling
#25
JOURNAL ARTICLE
Yuto Naoi, Takao Morinaga, Joji Nagasaki, Ryo Ariyasu, Youki Ueda, Kazuo Yamashita, Wenhao Zhou, Shusuke Kawashima, Katsushige Kawase, Akiko Honobe-Tabuchi, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yu Kawahara, Yasuhiro Nakamura, Yukiko Kiniwa, Osamu Yamasaki, Satoshi Fukushima, Masahito Kawazu, Yutaka Suzuki, Hiroyoshi Nishikawa, Toyoyuki Hanazawa, Mizuo Ando, Takashi Inozume, Yosuke Togashi
T cell exhaustion is a major contributor to immunosuppression in the tumor microenvironment (TME). Blockade of key regulators of T cell exhaustion, such as PD-1, can reinvigorate tumor-specific T cells and activate anti-tumor immunity in various types of cancer. Here, we identified that CD106 was specifically expressed in exhausted CD8+ T cells in the TME using single-cell RNA-sequencing. High CD106 expression in the TME in clinical samples corresponded to improved response to cancer immunotherapy. CD106 in tumor-specific T cells suppressed anti-tumor immunity both in vitro and in vivo, and loss of CD106 in CD8+ T cells suppressed tumor growth and improved response to PD-1 blockade...
April 18, 2024: Cancer Research
https://read.qxmd.com/read/38635884/crispr-cas9-screening-identifies-kras-induced-cox-2-as-a-driver-of-immunotherapy-resistance-in-lung-cancer
#26
JOURNAL ARTICLE
Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Philip East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward
Oncogenic KRAS impairs anti-tumor immune responses. As effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive, a better understanding of how oncogenic KRAS drives immune evasion is needed to identify approaches that could sensitize KRAS-mutant lung cancer to immunotherapy. In vivo CRISPR-Cas9 screening in an immunogenic murine lung cancer model identified mechanisms by which oncogenic KRAS promotes immune evasion, most notably via upregulation of immunosuppressive cyclooxygenase-2 (COX-2) in cancer cells...
April 18, 2024: Cancer Research
https://read.qxmd.com/read/38635069/necroptosis-related-lncrna-based-novel-signature-to-predict-the-prognosis-and-immune-landscape-in-soft-tissue-sarcomas
#27
JOURNAL ARTICLE
Qiuzhong Long, Zhengtian Li, Wenkang Yang, Ke Huang, Gang Du
BACKGROUND: Necroptosis-related long noncoding RNAs (lncRNAs) play crucial roles in cancer initiation and progression. Nevertheless, the role and mechanism of necroptosis-related lncRNAs in soft tissue sarcomas (STS) is so far unknown and needs to be explored further. METHODS: Clinical and genomic data were obtained from the UCSC Xena database. All STS patients' subclusters were performed by unsupervised consensus clustering method based on the prognosis-specific lncRNAs, and then assessed their survival advantage and immune infiltrates...
April 18, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38634572/gbm-immunotherapy-macrophage-impacts
#28
REVIEW
Nina Loginova, Denis Aniskin, Peter Timashev, Ilya Ulasov, Rajesh Kumar Kharwar
BACKGROUND: Glioblastoma (GBM) is an extremely aggressive form of brain tumor with low survival rates. Current treatments such as chemotherapy, radiation, and surgery are problematic due to tumor growth, invasion, and tumor microenvironment. GBM cells are resistant to these standard treatments, and the heterogeneity of the tumor makes it difficult to find a universal approach. Progression of GBM and acquisition of resistance to therapy are due to the complex interplay between tumor cells and the TME...
April 18, 2024: Immunological Investigations
https://read.qxmd.com/read/38634521/cell-membrane-coated-nanoparticles-as-a-biomimetic-drug-delivery-platform-for-enhancing-cancer-immunotherapy
#29
REVIEW
Zichen Zhong, Wen Deng, Jian Wu, Haojie Shang, Yonghua Tong, Yu He, Qiu Huang, Xiaozhuo Ba, Zhiqiang Chen, Kun Tang
Cancer immunotherapy, a burgeoning modality for cancer treatment, operates by activating the autoimmune system to impede the growth of malignant cells. Although numerous immunotherapy strategies have been employed in clinical cancer therapy, the resistance of cancer cells to immunotherapeutic medications and other apprehensions impede the attainment of sustained advantages for most patients. Recent advancements in nanotechnology for drug delivery hold promise in augmenting the efficacy of immunotherapy. However, the efficacy is currently constrained by the inadequate specificity of delivery, low rate of response, and the intricate immunosuppressive tumor microenvironment...
April 18, 2024: Nanoscale
https://read.qxmd.com/read/38633865/dual-regulation-of-osteosarcoma-hypoxia-microenvironment-by-a-bioinspired-oxygen-nanogenerator-for-precise-single-laser-synergistic-photodynamic-photothermal-induced-antitumor-immunity-therapy
#30
JOURNAL ARTICLE
Chongqing Zhang, Dongsheng Li, Xin Zhang, Rong Dai, Weiwei Kang, Yao Li, Qin Liu, Mengting Gao, Ziliang Zheng, Ruiping Zhang, Zhaohui Wen
The hypoxic tumor microenvironment (TME) of osteosarcoma (OS) is the Achilles' heel of oxygen-dependent photodynamic therapy (PDT), and tremendous challenges are confronted to reverse the hypoxia. Herein, we proposed a "reducing expenditure of O2 and broadening sources" dual-strategy and constructed ultrasmall IrO2 @BSA-ATO nanogenerators (NGs) for decreasing the O2 -consumption and elevating the O2 -supply simultaneously. As O2 NGs, the intrinsic catalase (CAT) activity could precisely decompose the overexpressed H2 O2 to produce O2 in situ, enabling exogenous O2 infusion...
June 2024: Materials today. Bio
https://read.qxmd.com/read/38632994/high-indoleamine-2-3-dioxygenase-transcript-levels-predict-better-outcome-after-front-line-cancer-immunotherapy
#31
JOURNAL ARTICLE
Yu Fujiwara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K Nesline, Jeffrey M Conroy, Paul DePietro, Sarabjot Pabla, Scott M Lippman, Razelle Kurzrock
Indoleamine 2,3-dioxygenase 1 (IDO1), which catabolizes tryptophan, is a potential target to unlock the immunosuppressive tumor microenvironment. Correlations between IDO1 and immune checkpoint inhibitor (ICI) efficacy remain unclear. Herein, we investigated IDO1 transcript expression across cancers and clinical outcome correlations. High IDO1 transcripts were more frequent in uterine (54.2%) and ovarian cancer (37.2%) but varied between and within malignancies. High IDO1 RNA expression was associated with high expression of PD-L1 (immune checkpoint ligand), CXCL10 (an effector T cell recruitment chemokine), and STAT1 (a component of the JAK-STAT pathway) (all multivariable p  < 0...
April 19, 2024: IScience
https://read.qxmd.com/read/38632387/single-cell-transcriptome-analysis-profiling-lymphatic-invasion-related-tme-in-colorectal-cancer
#32
JOURNAL ARTICLE
Liping Wang, Liming Ma, Zhaona Song, Li Zhou, Kexin Chen, Xizi Wang, Zhen Liu, Baozhong Wang, Chen Shen, Xianchao Guo, Xiaodong Jia
Lymphatic invasion (LI) is extremely aggressive and induces worse prognosis among patients with colorectal cancer (CRC). Thus, it is critical to characterize the cellular and molecular mechanisms underlying LI in order to establish novel and efficacious therapeutic targets that enhance the prognosis of CRC patients. RNA-seq data, clinical and survival information of colon adenocarcinoma (COAD) patients were obtained from the TCGA database. In addition, three scRNA-seq datasets of CRC patients were acquired from the GEO database...
April 17, 2024: Scientific Reports
https://read.qxmd.com/read/38632255/the-prognostic-value-of-sialylation-related-long-non-coding-rnas-in-lung-adenocarcinoma
#33
JOURNAL ARTICLE
Beiru Wang, Chengyu Hou, Xiang Yu, Jiaxin Liu, Jiyong Wang
There has been increasing interest in the role of epigenetic modification in cancers recently. Among the various modifications, sialylation has emerged as a dominant subtype implicated in tumor progression, metastasis, immune evasion, and chemoresistance. The prognostic significance of sialylation-related molecules has been demonstrated in colorectal cancer. However, the potential roles and regulatory mechanisms of sialylation in lung adenocarcinoma (LUAD) have not been thoroughly investigated. Through Pearson correlation, univariate Cox hazards proportional regression, and random survival forest model analyses, we identified several prognostic long non-coding RNAs (lncRNAs) associated with aberrant sialylation and tumor progression, including LINC00857, LINC00968, LINC00663, and ITGA9-AS1...
April 17, 2024: Scientific Reports
https://read.qxmd.com/read/38631709/preclinical-evaluation-of-two-phylogenetically-distant-arenavirus-vectors-for-the-development-of-novel-immunotherapeutic-combination-strategies-for-cancer-treatment
#34
JOURNAL ARTICLE
Josipa Raguz, Catarina Pinto, Theresa Pölzlbauer, Mohamed Habbeddine, Sandra Rosskopf, Judith Strauß, Valentin Just, Sarah Schmidt, Katell Bidet Huang, Felix Stemeseder, Timo Schippers, Ethan Stewart, Jakub Jez, Pedro Berraondo, Klaus K Orlinger, Henning Lauterbach
BACKGROUND: Engineered arenavirus vectors have recently been developed to leverage the body's immune system in the fight against chronic viral infections and cancer. Vectors based on Pichinde virus (artPICV) and lymphocytic choriomeningitis virus (artLCMV) encoding a non-oncogenic fusion protein of human papillomavirus (HPV)16 E6 and E7 are currently being tested in patients with HPV16+ cancer, showing a favorable safety and tolerability profile and unprecedented expansion of tumor-specific CD8+ T cells...
April 17, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38629071/single-cell-rna-seq-reveals-t-cell-exhaustion-and-immune-response-landscape-in-osteosarcoma
#35
JOURNAL ARTICLE
Qizhi Fan, Yiyan Wang, Jun Cheng, Boyu Pan, Xiaofang Zang, Renfeng Liu, Youwen Deng
BACKGROUND: T cell exhaustion in the tumor microenvironment has been demonstrated as a substantial contributor to tumor immunosuppression and progression. However, the correlation between T cell exhaustion and osteosarcoma (OS) remains unclear. METHODS: In our present study, single-cell RNA-seq data for OS from the GEO database was analysed to identify CD8+ T cells and discern CD8+ T cell subsets objectively. Subgroup differentiation trajectory was then used to pinpoint genes altered in response to T cell exhaustion...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38628755/integrated-single-cell-and-spatial-transcriptomic-analysis-reveals-ybx1-drives-immune-regulation-in-gbm-progression
#36
JOURNAL ARTICLE
Yanshan Ge, Huiting Weng, Yingnan Sun, Minghua Wu
The RNA modification 5-methylcytosine (m5C) is widespread across various RNA types, significantly impacting RNA stability and translational efficiency. Accumulating evidence highlights its significant role within the tumorigenesis and progression of multiple malignancies. Nevertheless, the specific process through m5C is implicated in Glioblastoma (GBM) remains unclear. We conducted acomprehensive analysis of m5C expression distribution in single-cell GBM data. Our findings revealed elevated m5C scores in GBM single-cell data compared to the normal group...
April 30, 2024: Heliyon
https://read.qxmd.com/read/38628676/dendritic-cell-based-immunotherapy-the-importance-of-dendritic-cell-migration
#37
REVIEW
Min-Seon Song, Ji-Hee Nam, Kyung-Eun Noh, Dae-Seog Lim
Dendritic cells (DCs) are specialized antigen-presenting cells that are crucial for maintaining self-tolerance, initiating immune responses against pathogens, and patrolling body compartments. Despite promising aspects, DC-based immunotherapy faces challenges that include limited availability, immune escape in tumors, immunosuppression in the tumor microenvironment, and the need for effective combination therapies. A further limitation in DC-based immunotherapy is the low population of migratory DC (around 5%-10%) that migrate to lymph nodes (LNs) through afferent lymphatics depending on the LN draining site...
2024: Journal of Immunology Research
https://read.qxmd.com/read/38628547/a-lipid-plga-nanocomplex-to-reshape-tumor-immune-microenvironment-for-colon-cancer-therapy
#38
JOURNAL ARTICLE
Nan Zhang, Qiqi Sun, Junhua Li, Jing Li, Lei Tang, Quan Zhao, Yuji Pu, Gaofeng Liang, Bin He, Wenxia Gao, Jianlin Chen
Immune checkpoint blockade therapy provides a new strategy for tumor treatment; however, the insufficient infiltration of cytotoxic T cells and immunosuppression in tumor microenvironment lead to unsatisfied effects. Herein, we reported a lipid/PLGA nanocomplex (RDCM) co-loaded with the photosensitizer Ce6 and the indoleamine 2,3-dioxygenase (IDO) inhibitor 1MT to improve immunotherapy of colon cancer. Arginine-glycine-aspartic acid (RGD) as the targeting moiety was conjugated on 1,2-distearoyl-snglycero-3-phosphoethanolamine lipid via polyethylene glycol (PEG), and programmed cell death-ligand 1 (PD-L1) peptide inhibitor DPPA (sequence: CPLGVRGK-GGG-d(NYSKPTDRQYHF)) was immobilized on the terminal group of PEG via matrix metalloproteinase 2 sensitive peptide linker...
2024: Regenerative Biomaterials
https://read.qxmd.com/read/38627665/pan-inhibition-of-the-three-h-2-s-synthesizing-enzymes-restrains-tumor-progression-and-immunosuppression-in-breast-cancer
#39
JOURNAL ARTICLE
Alyaa Dawoud, Rana A Youness, Heba Nafea, Tamer Manie, Carole Bourquin, Csaba Szabo, Reham M Abdel-Kader, Mohamed Z Gad
BACKGROUND: Hydrogen sulfide (H2 S) is a significant endogenous mediator that has been implicated in the progression of various forms of cancer including breast cancer (BC). Cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3MST) are the three principal mammalian enzymes responsible for H2 S production. Overexpression of CBS, CSE and 3MST was found to be associated with poor prognosis of BC patients. Moreover, H2 S was linked to an immune-suppressive tumor microenvironment in BC...
April 16, 2024: Cancer Cell International
https://read.qxmd.com/read/38626916/superparamagnetic-iron-oxide-nanoparticles-reprogram-the-tumor-microenvironment-and-reduce-lung-cancer-regrowth-after-crizotinib-treatment
#40
JOURNAL ARTICLE
Natalie K Horvat, Sara Chocarro, Oriana Marques, Tobias A Bauer, Ruiyue Qiu, Alberto Diaz-Jimenez, Barbara Helm, Yuanyuan Chen, Stefan Sawall, Richard Sparla, Lu Su, Ursula Klingmüller, Matthias Barz, Matthias W Hentze, Rocío Sotillo, Martina U Muckenthaler
ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor (TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor survival rates. Growing evidence suggests that the combination of drug and immune therapies greatly improves patient survival; however, due to the low immunogenicity of the tumors, ALK-positive patients do not respond to currently available immunotherapies. Tumor-associated macrophages (TAMs) play a crucial role in facilitating lung cancer growth by suppressing tumoricidal immune activation and absorbing chemotherapeutics...
April 16, 2024: ACS Nano
keyword
keyword
164288
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.